Skip to Primary Navigation

Skip to main content

DOJ’s bulk sensitive personal data rule: Life sciences compliance

A nurse checks a patient's medical records in Sichuan province, China.
Photo: Paula Bronstein/Getty Images

Todd Liao | Morgan Lewis, David Plotinsky | Morgan Lewis, Carl Valenstein | Morgan Lewis+1

7 min read
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.

For the life sciences industry, the flow of human genomic data, biospecimens, and clinical trial records across borders is not merely an operational detail, it is the lifeblood of global research and development. But the regulatory environment governing the flow of this data and materials has shifted dramatically.

Now at

, , , , , , , , , , , , , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience